|Articles|October 19, 2007
A Healthy Outlook for Oncology?
The oncology market has experienced ten remarkable years. But is the 'Golden Age' coming to an end? IMS Health looks at the changing economics of the cancer industry in Pharm Exec Europe's new e-supplement.
Advertisement
The oncology market has experienced ten remarkable years. But is the 'Golden Age' coming to an end?
IMS Health looks at the changing economics of the cancer industry in Pharm Exec Europe's new e-supplement.
Click
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
2
Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio
3
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
4
The Evolving Relationship Between FDA and Biotech
5